Evaluating Riociguat in the Treatment of Pulmonary Arterial Hypertension: A Real-World Perspective.
chronic thromboembolic pulmonary hypertension
pulmonary arterial hypertension
riociguat
soluble guanylate cyclase stimulator
Journal
Vascular health and risk management
ISSN: 1178-2048
Titre abrégé: Vasc Health Risk Manag
Pays: New Zealand
ID NLM: 101273479
Informations de publication
Date de publication:
2022
2022
Historique:
received:
24
07
2022
accepted:
12
10
2022
entrez:
27
10
2022
pubmed:
28
10
2022
medline:
29
10
2022
Statut:
epublish
Résumé
Pulmonary hypertension (PH) is a broad term describing the mean pulmonary artery pressure, as measured by right heart catheterization, exceeds 20mmHg. Pulmonary arterial hypertension (PAH) exists when PH is accompanied by a normal wedge pressure and elevated pulmonary vascular resistance. PAH is typified by dysmorphic and dysfunctional pulmonary arterial vasculature. Attempting to restore the functionality of the pulmonary artery is a hallmark of care to the PAH patient. Riociguat is a powerful stimulator of soluble guanylate cyclase and increases blood flow through the pulmonary arteries by dilating vascular smooth muscle cells. This review examines the pharmacology of riociguat, the fundamental clinical trials applying it to PAH patients, practical aspects when selecting its use, and future directions for its utilization.
Identifiants
pubmed: 36299800
doi: 10.2147/VHRM.S383572
pii: 383572
pmc: PMC9590350
doi:
Substances chimiques
riociguat
RU3FE2Y4XI
Soluble Guanylyl Cyclase
EC 4.6.1.2
Pyrazoles
0
Pyrimidines
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
823-832Informations de copyright
© 2022 Mihalek et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
Pulm Circ. 2019 Feb 26;:2045894019837849
pubmed: 30803329
Pulm Circ. 2019 Apr-Jun;9(2):2045894019848644
pubmed: 30997864
Lung. 2018 Jun;196(3):305-312
pubmed: 29470642
N Engl J Med. 2013 Jul 25;369(4):330-40
pubmed: 23883378
N Engl J Med. 2020 May 14;382(20):1883-1893
pubmed: 32222134
Am J Respir Crit Care Med. 2021 Oct 1;204(7):756-759
pubmed: 34402773
BMC Pulm Med. 2016 May 18;16(1):82
pubmed: 27193179
N Engl J Med. 2004 Feb 26;350(9):886-95
pubmed: 14985486
Chest. 2018 Jul;154(1):136-147
pubmed: 29275134
Am J Respir Crit Care Med. 2008 Mar 1;177(5):506-15
pubmed: 18006891
Ther Adv Respir Dis. 2021 Jan-Dec;15:1753466621995048
pubmed: 33627044
Heart Lung Circ. 2020 Mar;29(3):331-336
pubmed: 30773322
J Heart Lung Transplant. 2021 Jun;40(6):494-503
pubmed: 33744088
Eur Respir J. 2017 Feb 23;49(2):
pubmed: 28232411
Int J Cardiol. 2021 Jun 1;332:189-192
pubmed: 33744348
Lancet Respir Med. 2021 Jun;9(6):573-584
pubmed: 33773120
Eur Respir J. 2008 Aug;32(2):296-302
pubmed: 18385166
J Cyst Fibros. 2021 Nov;20(6):1018-1025
pubmed: 34419414
J Biol Chem. 1998 Jul 24;273(30):18709-13
pubmed: 9668042
N Engl J Med. 2015 Dec 24;373(26):2522-33
pubmed: 26699168
J Am Coll Cardiol. 2021 Oct 5;78(14):1393-1403
pubmed: 34593120
Eur Respir J. 2019 Jan 24;53(1):
pubmed: 30545980
N Engl J Med. 2013 Jul 25;369(4):319-29
pubmed: 23883377
Eur Respir J. 2019 Oct 31;54(4):
pubmed: 31320453
Wien Klin Wochenschr. 2016 Dec;128(23-24):882-889
pubmed: 27590259
Circulation. 2013 Jul 30;128(5):502-11
pubmed: 23775260
Eur Respir J. 2019 Jan 24;53(1):
pubmed: 30545968
Ann Rheum Dis. 2020 May;79(5):618-625
pubmed: 32299845
Lancet Respir Med. 2019 Nov;7(11):e35
pubmed: 31645285
Int J Cardiol. 2005 Mar 10;99(1):91-5
pubmed: 15721505
Pulm Circ. 2017 Apr-Jun;7(2):539-542
pubmed: 28597779
Chest. 2014 Jan;145(1):30-36
pubmed: 24394821
Pulm Circ. 2018 Jan-Mar;8(1):2045893217743123
pubmed: 29099661
Respir Med. 2017 Jan;122 Suppl 1:S18-S22
pubmed: 27887774
N Engl J Med. 1995 Jul 27;333(4):214-21
pubmed: 7540722
Eur Respir J. 2019 Jan 24;53(1):
pubmed: 30545969
Ann Rheum Dis. 2012 Jun;71(6):1019-26
pubmed: 22294631
Lancet Respir Med. 2019 Sep;7(9):780-790
pubmed: 31416769
Pulm Circ. 2016 Mar;6(Suppl 1):S49-57
pubmed: 27162627
Circ Rep. 2021 Jan 9;3(2):105-109
pubmed: 33693297
Ann Rheum Dis. 2017 Feb;76(2):422-426
pubmed: 27457511
N Engl J Med. 2005 May 12;352(19):1992-2001
pubmed: 15888700
Am J Respir Crit Care Med. 2005 Mar 1;171(5):506-13
pubmed: 15579730
Eur Respir J. 2017 Sep 9;50(3):
pubmed: 28889107
Eur Respir J. 2019 Jan 24;53(1):
pubmed: 30545974
Pulm Circ. 2019 Jan-Mar;9(1):2045894019826944
pubmed: 30638432
Respir Med Case Rep. 2017 Jun 10;22:39-43
pubmed: 28652963
Eur Respir J. 2015 May;45(5):1314-22
pubmed: 25657022
Pulm Circ. 2022 Apr 07;12(2):e12055
pubmed: 35514769
Eur Respir J. 2015 May;45(5):1303-13
pubmed: 25614164
Chest. 2022 Feb;161(2):448-457
pubmed: 34363816
N Engl J Med. 2021 Dec 16;385(25):2361-2376
pubmed: 34910865
Ann Am Thorac Soc. 2016 Jul;13 Suppl 3:S201-6
pubmed: 27571001
Expert Opin Drug Metab Toxicol. 2019 Nov;15(11):975-984
pubmed: 31619082
Am J Cardiovasc Drugs. 2018 Aug;18(4):249-257
pubmed: 29511993
Pulm Circ. 2017 Jul-Sep;7(3):741-746
pubmed: 28671485
Lancet Respir Med. 2021 Jun;9(6):546-547
pubmed: 33773119
N Engl J Med. 2009 May 7;360(19):1989-2003
pubmed: 19420368
Pulm Circ. 2018 Apr-Jun;8(2):2045894018769305
pubmed: 29565224
Nat Rev Cardiol. 2018 May;15(5):292-316
pubmed: 29388567
Am J Respir Crit Care Med. 1998 Oct;158(4):1061-7
pubmed: 9769261
Clin Pharmacokinet. 2016 May;55(5):615-24
pubmed: 26507720
Future Cardiol. 2014 Mar;10(2):163
pubmed: 24883440